Les tests génétiques peuvent-ils identifier des facteurs de risque ?
Oui, les tests peuvent révéler des mutations génétiques associées à des maladies héréditaires.
Tests génétiquesMutations
#5
Comment réduire les facteurs de risque ?
On peut réduire les facteurs de risque par des choix de vie sains et un suivi médical régulier.
Réduction des risquesSuivi médical
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Pedigree : Questions médicales les plus fréquentes",
"headline": "Pedigree : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Pedigree : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-28",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Pedigree"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Techniques génétiques",
"url": "https://questionsmedicales.fr/mesh/D005821",
"about": {
"@type": "MedicalCondition",
"name": "Techniques génétiques",
"code": {
"@type": "MedicalCode",
"code": "D005821",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.393"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Pedigree",
"alternateName": "Pedigree",
"code": {
"@type": "MedicalCode",
"code": "D010375",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Pablo Gutiérrez",
"url": "https://questionsmedicales.fr/author/Juan%20Pablo%20Guti%C3%A9rrez",
"affiliation": {
"@type": "Organization",
"name": "Departamento de Producción Animal, Facultad de Veterinaria UCM Madrid Spain."
}
},
{
"@type": "Person",
"name": "Hong Zhang",
"url": "https://questionsmedicales.fr/author/Hong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Renal Division, Department of Medicine, Peking University First Hospital Beijing 100034, China."
}
},
{
"@type": "Person",
"name": "Kenjiro Kosaki",
"url": "https://questionsmedicales.fr/author/Kenjiro%20Kosaki",
"affiliation": {
"@type": "Organization",
"name": "Center for Medical Genetics Keio University School of Medicine Tokyo Japan."
}
},
{
"@type": "Person",
"name": "Magnus Dehli Vigeland",
"url": "https://questionsmedicales.fr/author/Magnus%20Dehli%20Vigeland",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Genetics, University of Oslo, Oslo, Norway. magnusdv@medisin.uio.no."
}
},
{
"@type": "Person",
"name": "Mengting Zhang",
"url": "https://questionsmedicales.fr/author/Mengting%20Zhang",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Completeness of variables in Hospital-Based Cancer Registries for prostatic malignant neoplasm.",
"datePublished": "2024-07-29",
"url": "https://questionsmedicales.fr/article/39082550",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0034-7167-2023-0467"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on 18 F-DCFPyl PET/CT.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36728165",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RLU.0000000000004554"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.",
"datePublished": "2022-12-27",
"url": "https://questionsmedicales.fr/article/36572885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12957-022-02841-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "The influence of prostate volume on clinical parameters in prostate cancer screening.",
"datePublished": "2022-09-13",
"url": "https://questionsmedicales.fr/article/36098911",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcla.24700"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Techniques génétiques",
"item": "https://questionsmedicales.fr/mesh/D005821"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pedigree",
"item": "https://questionsmedicales.fr/mesh/D010375"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Pedigree - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Pedigree",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Pedigree",
"description": "Comment établir un pedigree familial ?\nQuels outils pour analyser un pedigree ?\nQuelle est l'importance du pedigree en médecine ?\nComment interpréter un pedigree ?\nQuelles maladies peuvent être identifiées par un pedigree ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Pedigree",
"description": "Quels symptômes peuvent indiquer une maladie héréditaire ?\nComment les symptômes varient selon les générations ?\nLes symptômes sont-ils toujours présents dans un pedigree ?\nPeut-on prédire des symptômes à partir d'un pedigree ?\nQuels sont les symptômes de la maladie de Huntington ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Pedigree",
"description": "Comment prévenir les maladies héréditaires ?\nLe dépistage prénatal est-il utile ?\nQuels tests génétiques sont recommandés ?\nComment le mode de vie influence-t-il la prévention ?\nLes vaccinations aident-elles à prévenir des maladies héréditaires ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Pedigree",
"description": "Comment le pedigree influence-t-il le traitement ?\nQuels traitements pour les maladies héréditaires ?\nLe dépistage précoce est-il important ?\nQuels sont les traitements pour la fibrose kystique ?\nComment les conseils génétiques aident-ils au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Pedigree",
"description": "Quelles complications peuvent survenir avec des maladies héréditaires ?\nComment gérer les complications des maladies héréditaires ?\nLes complications sont-elles prévisibles ?\nQuelles sont les complications de la maladie de Tay-Sachs ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Pedigree",
"description": "Quels sont les facteurs de risque pour les maladies héréditaires ?\nComment les antécédents familiaux influencent-ils le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes tests génétiques peuvent-ils identifier des facteurs de risque ?\nComment réduire les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D010375?mesh_terms=Prostatic+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment établir un pedigree familial ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un pedigree est établi en collectant des informations sur les membres de la famille et leurs maladies."
}
},
{
"@type": "Question",
"name": "Quels outils pour analyser un pedigree ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des logiciels de généalogie et des diagrammes sont utilisés pour visualiser les relations et les maladies."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du pedigree en médecine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à identifier les risques héréditaires et à orienter le dépistage et le traitement."
}
},
{
"@type": "Question",
"name": "Comment interpréter un pedigree ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "On analyse les symboles et les lignes pour comprendre les transmissions héréditaires."
}
},
{
"@type": "Question",
"name": "Quelles maladies peuvent être identifiées par un pedigree ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme la fibrose kystique, la maladie de Huntington et d'autres troubles génétiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une maladie héréditaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme des anomalies congénitales, des troubles métaboliques ou neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient selon les générations ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître différemment selon les générations en raison de la variabilité génétique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents dans un pedigree ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains porteurs de gènes peuvent ne pas exprimer de symptômes visibles."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des symptômes à partir d'un pedigree ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un pedigree peut aider à prédire la probabilité d'apparition de certains symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la maladie de Huntington ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles moteurs, cognitifs et psychiatriques, souvent visibles à l'âge adulte."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies héréditaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le dépistage, le conseil génétique et des choix de vie sains."
}
},
{
"@type": "Question",
"name": "Le dépistage prénatal est-il utile ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il permet de détecter certaines maladies génétiques avant la naissance."
}
},
{
"@type": "Question",
"name": "Quels tests génétiques sont recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour des maladies spécifiques peuvent être recommandés selon les antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque d'expression de certaines maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir des maladies héréditaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations ne préviennent pas les maladies héréditaires, mais elles préviennent d'autres infections."
}
},
{
"@type": "Question",
"name": "Comment le pedigree influence-t-il le traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet de personnaliser les traitements en fonction des antécédents familiaux et des risques."
}
},
{
"@type": "Question",
"name": "Quels traitements pour les maladies héréditaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements varient, incluant la thérapie génique, les médicaments et la gestion des symptômes."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il important ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il permet d'initier un traitement précoce et d'améliorer le pronostic des maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements pour la fibrose kystique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments, des thérapies respiratoires et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Comment les conseils génétiques aident-ils au traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des informations sur les risques et les options de traitement pour les familles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des maladies héréditaires ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications variées comme des troubles organiques, des handicaps ou des maladies associées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des maladies héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical régulier et des traitements adaptés aux complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles grâce à l'analyse du pedigree et des antécédents."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la maladie de Tay-Sachs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques graves et une espérance de vie réduite."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un dépistage et une intervention précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les maladies héréditaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des facteurs environnementaux."
}
},
{
"@type": "Question",
"name": "Comment les antécédents familiaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies augmentent la probabilité de développer des conditions similaires."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent interagir avec des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils identifier des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests peuvent révéler des mutations génétiques associées à des maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Comment réduire les facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "On peut réduire les facteurs de risque par des choix de vie sains et un suivi médical régulier."
}
}
]
}
]
}
to analyze the completeness of variables from Hospital-Based Cancer Registries of cases of prostate neoplasm in the Oncology Care Network of a Brazilian state between 2000 and 2020....
an ecological time series study, based on secondary data on prostate cancer Hospital-Based Cancer Registries prostate. Data incompleteness was classified as excellent (<5%), good (between 5%-10%), fai...
there were 13,519 cases of prostate cancer in the Hospital-Based Cancer Registries analyzed. The variables "family history of cancer" (p<0.001), "alcoholism" (p<0.001), "smoking" (p<0.001), "TNM stagi...
most Hospital-Based Cancer Registries variables showed excellent completeness, but important variables had high percentages of incompleteness, such as TNM and clinical staging, in addition to alcoholi...
18 F-DCFPyl is a Food and Drug Administration-approved radiotracer that targets prostate-specific membrane antigen and is used in the detection of recurrent or metastatic prostate cancer. As its use h...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers co...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges....
The serum metabolites of 20 healthy individuals and patients with prostatitis, BPH, or PCa were identified using untargeted liquid chromatography-mass spectrometry (LC-MS). In addition, targeted LC-MS...
Organic acid metabolites had good sensitivity and specificity in differentiating prostatitis, BPH, and PCa. Three diagnostic models identified patients with PROSTATITIS: phenyllactic acid (area under ...
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...